Latest Breaking News On - Joan shen - Page 1 : comparemela.com

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

Joan shenNeushen therapeutics the companyChina national medical products administrationNeushen therapeuticsNational medical products administration

I-Mab Gets New CEO After Long Search Sale Of The Company Coming Next? - I-MAB (NASDAQ:IMAB), AbbVie (NYSE:ABBV)

Key Takeaways: I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit The new CEO is an industry veteran who engineered sales of his previous two companies after bringing their first drugs to market, hinting that I-Mab could follow a similar path By Warren Yang

Hong kongZang jingwuWarren yangRaj kannanInnovent biologicsJoan shenAndrew zhuU aerie pharmaceuticalsAmryt pharma plcChiasma incKey takeawaysAerie pharmaceuticalsChairman zang jingwuSouth korea basedWuxi biologicsI mab chairman zang

Week In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million Value

Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.

Hong kongUnited statesSihuan pharmaXuanzhu biopharmHuisheng biopharmSeattle seagenKiomed pharmaJoan shenHansoh pharmaSichuan kelunSimcere pharmaNasdaq exchangeZai labHorae gene therapy centerCell researchShanghai zai lab

NeuShen Therapeutics Closes Approx $20M Pre-A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesJoan shenShen therapeuticsNeushen therapeutics

NeuShen Therapeutics Closes Pre-A Financing with ~$20M

/PRNewswire/ NeuShen Therapeutics, Inc., a biotechnology company focusing on developing innovative treatments for central nervous system (CNS) disorders.

United statesYahong meditechGuangping gaoJoan shenZhihua yuLilly zhangAibo medical robot coPrnewswire neushen therapeutics incRemegen coHorae gene therapy centerBiostar pharmaceuticalsUmass chan medical schoolShen therapeuticsChan medicalManaging directorScientific advisory